The Effect of Aspirin on the Prevention of Pro-thrombotic States in Hospitalized COVID-19 Patients: Systematic Review / Masoumeh Abdi, Zahra Hoseini Lamardi, Fatemeh Shirjan, Leila Mohammadi, Sahel Shafiee Dolat Abadi, Nilofar Massoudi, Moein Zangiabadian, Mohammad Javad Nasiri
Introduction: Thromboembolic events are one of the important complications in COVID-19 patients, especially in severe cases. Aspirin affects platelet function by irreversibly inhibiting cyclooxygenase activity, reducing the risk of thrombosis. The current systematic review aimed to evaluate aspirin's effectiveness in preventing pro-thrombotic states in COVID-19 hospitalized patients. Methods: The systematic search was done in PubMed/Medline, EMBASE, and Medrxiv until September 27, 2021. The following keywords were used: “COVID-19”, “SARS-CoV-2”, “2019 Novel Coronavirus”, “Aspirin,” and “Acetylsalicylic Acid.” Results: Twelve studies were included. In COVID-19 patients, aspirin can reduce CRP, IL-6 levels, and platelet aggregation by inhibiting thromboxane A2. It can also improve antiviral immunity by hindering the biosynthesis of prostaglandins and lipoxin. Eight out of twelve articles indicated that aspirin provided a beneficial effect on COVID-19. Most studies consider lowered mechanical ventilation needs, ICU admission, illness severity, overt thrombosis, and clinical outcomes in COVID-19 patients receiving aspirin. Conclusion: Aspirin as an antiplatelet and anti-inflammatory agent may reduce the mortality rates in hospitalized patients with severe COVID-19. Further observational studies are necessary to determine the effect of aspirin on the prevention of pro-thrombotic states in hospitalized COVID- 19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Cardiovascular & hematological agents in medicinal chemistry - 20(2022), 3, Seite 8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdi, Masoumeh [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (8 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011163941 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011163941 | ||
| 003 | DE-627 | ||
| 005 | 20231128150423.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011163941 | ||
| 035 | |a (KFL)prod_DARH_.058E3D38687673C2470EE5618CA6497D045E60BA | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Abdi, Masoumeh |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Effect of Aspirin on the Prevention of Pro-thrombotic States in Hospitalized COVID-19 Patients: Systematic Review |c Masoumeh Abdi, Zahra Hoseini Lamardi, Fatemeh Shirjan, Leila Mohammadi, Sahel Shafiee Dolat Abadi, Nilofar Massoudi, Moein Zangiabadian, Mohammad Javad Nasiri |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (8 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction: Thromboembolic events are one of the important complications in COVID-19 patients, especially in severe cases. Aspirin affects platelet function by irreversibly inhibiting cyclooxygenase activity, reducing the risk of thrombosis. The current systematic review aimed to evaluate aspirin's effectiveness in preventing pro-thrombotic states in COVID-19 hospitalized patients. Methods: The systematic search was done in PubMed/Medline, EMBASE, and Medrxiv until September 27, 2021. The following keywords were used: “COVID-19”, “SARS-CoV-2”, “2019 Novel Coronavirus”, “Aspirin,” and “Acetylsalicylic Acid.” Results: Twelve studies were included. In COVID-19 patients, aspirin can reduce CRP, IL-6 levels, and platelet aggregation by inhibiting thromboxane A2. It can also improve antiviral immunity by hindering the biosynthesis of prostaglandins and lipoxin. Eight out of twelve articles indicated that aspirin provided a beneficial effect on COVID-19. Most studies consider lowered mechanical ventilation needs, ICU admission, illness severity, overt thrombosis, and clinical outcomes in COVID-19 patients receiving aspirin. Conclusion: Aspirin as an antiplatelet and anti-inflammatory agent may reduce the mortality rates in hospitalized patients with severe COVID-19. Further observational studies are necessary to determine the effect of aspirin on the prevention of pro-thrombotic states in hospitalized COVID- 19 patients | ||
| 700 | 1 | |a Lamardi, Zahra Hoseini |e verfasserin |4 aut | |
| 700 | 1 | |a Shirjan, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadi, Leila |e verfasserin |4 aut | |
| 700 | 1 | |a Abadi, Sahel Shafiee Dolat |e verfasserin |4 aut | |
| 700 | 1 | |a Massoudi, Nilofar |e verfasserin |4 aut | |
| 700 | 1 | |a Zangiabadian, Moein |e verfasserin |4 aut | |
| 700 | 1 | |a Nasiri, Mohammad Javad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular & hematological agents in medicinal chemistry |d Sharjah, U.A.E. : Bentham Science Publishers, 2006 |g 20(2022), 3, Seite 8 |h Online-Ressource |w (DE-627)KFL00000653X |w (DE-600)2254230-9 |w (DE-576)273891049 |x 1875-6182 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2022 |g number:3 |g pages:8 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5257&volume=20&issue=3&spage=189 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2022 |e 3 |h 8 | ||